OS Therapies Inc. Form 8-K Summary
Business Context and Reporting Period
Company: OS Therapies Inc. (OSTX), a clinical-stage biopharmaceutical company focused on ADC and immunotherapy research.
Reporting Date: December 31, 2024.
Event: Closing of a private placement financing and execution of a waiver agreement with an existing investor.
Key Financial Metrics and Capital Structure
- Gross Proceeds: Approximately $6,050,000 raised from the private placement.
- Securities Issued: 1,512,500 Units, each consisting of one share of Series A Senior Convertible Preferred Stock and one warrant to purchase one share of common stock.
- Price per Unit: $4.00.
- Transaction Costs: Cash fees of $124,528 to placement agent Brookline Capital Markets and $62,171 to dealer Ceros Financial Services. Additional agent warrants issued for 31,130 and 15,542 shares respectively.
- Debt and Liquidity: The filing does not provide specific balance sheet data regarding total debt, cash on hand, or liquidity ratios prior to this transaction.
Material Changes and Agreements
- Private Placement Closing: Completed on December 31, 2024, with institutional and accredited investors.
- Series A Preferred Stock Terms:
- Liquidation Preference: 150% of the original issue price.
- Voting Rights: One vote per share on an as-converted basis, subject to a voting price floor.
- Mandatory Conversion Triggers: Conversion is mandatory upon a qualified public offering or PIPE financing raising over $10M or $20M respectively at a price not less than $12.00 per share; a third-party acquisition at a cash price not less than $12.00 per share; or if the daily VWAP exceeds 300% of the conversion price for 20 consecutive trading days with minimum volume of $2.0 million.
- Issuance Restrictions: The company is restricted from issuing additional common stock or variable rate transactions for six months post-closing or until stockholder approval is obtained, whichever is later.
- ELOC Investor Waiver: Entered into a waiver with Square Gate Capital Master Fund, LLC-Series 3 regarding a prior Equity Purchase Agreement.
- Compensation: The company agreed to make cash payments (one paid Jan 2, 2025, one held in escrow) and issue additional common stock valued at $118,230.62 to the ELOC Investor.
Guidance, Outlook, and Risks
- Registration Rights: The company agreed to file a registration statement within 30 days of closing covering the resale of shares underlying the Series A Preferred Stock and Warrants (up to 300% of initial issuance) and to seek effectiveness within 45 days.
- Stockholder Approval: A Voting Agreement was executed with certain officers and directors to vote in favor of proposals required for NYSE American approval of the transaction.
- Risks: The filing highlights restrictions on future capital raising activities (issuance of common stock or variable rate transactions) until specific conditions are met. The escrowed payment to the ELOC Investor is contingent on the effectiveness of the registration statement.
Investor Verification Checklist
- Verify the exact number of shares issued as "Additional Shares" to the ELOC Investor once the registration statement filing date is confirmed.
- Monitor the status of the registration statement for the resale of the Series A Preferred Stock and Warrants to ensure it is declared effective within the 45-day window.
- Review the full text of the Certificate of Designation for Series A Preferred Stock to understand specific voting thresholds and conversion mechanics.
- Confirm the release conditions for the escrowed cash payment to the ELOC Investor.
- Check for any subsequent filings regarding stockholder approval required by NYSE American rules.